Amy DeZern, MD, MHS, is an Associate Professor of Oncology and Medicine at Johns Hopkins University School of Medicine, Baltimore, MD, and a hematologist and medical oncologist based at the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Dr DeZern earned her medical degree at Johns Hopkins University, before completing a residency in internal medicine and fellowships in medical oncology and hematology. She also undertook a master’s degree in Clinical Investigations at the Bloomberg School of Public Health.
Dr DeZern is Director of the bone marrow failure (BMF) and MDS program at Johns Hopkins. She is a nationally renowned authority in the fields of BMF, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as an expert in alternative donor bone marrow transplant. She is heavily involved in clinical trials in these areas and has been awarded the NCI Cancer Clinical Investigator Team Leadership Award. Her work has also been recognized with the Director’s Teaching Award from The Sidney Kimmel Comprehensive Cancer Center, 2013 – 2020.
Speaking on clinical investigations in bone marrow failure and MDS
Dr DeZern has significant expertise in BMF syndromes and myeloid neoplasms. Her research surrounds diagnosis and treatment of these conditions, particularly translational efforts for novel treatments. She has served as principal investigator for numerous multicenter trials of novel treatments for BMF. Her pioneering work has changed standard of care approaches for aplastic anemia, been the basis for novel drug approvals in MDS, and introduced frontline haploidentical transplant in aplastic anemia. Dr DeZern is the study chair for the major CHAMP study, optimizing haploidentical donor transplantation in aplastic anemia, as well as Deputy Chair for The National MDS Study.
Sorry, no posts matched your criteria.